Previous studies have shown that ST6GAL1 is upregulated in CRC and various other malignancies, and that its elevated expression is associated with tumor progression, metastasis, and poor prognosis.[12, 13, 14, 15, 16] Consistent with these findings, our data demonstrated that knockdown of ST6GAL1 suppressed CRC cell proliferation, migration, and tumorigenicity both in vitro and in vivo. The gene discussed is ST6GAL1; the disease is neoplasm.